Prestige Biologics Z Score vs. Cash And Equivalents
| 334970 Stock | KRW 5,330 360.00 6.33% |
For Prestige Biologics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Prestige Biologics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Prestige Biologics Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Prestige Biologics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Prestige Biologics Co over time as well as its relative position and ranking within its peers.
Prestige |
Prestige Biologics Cash And Equivalents vs. Z Score Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Prestige Biologics's current stock value. Our valuation model uses many indicators to compare Prestige Biologics value to that of its competitors to determine the firm's financial worth. Prestige Biologics Co is rated below average in z score category among its peers. It is rated second in cash and equivalents category among its peers creating about 30,644,482,958 of Cash And Equivalents per Z Score. Comparative valuation analysis is a catch-all model that can be used if you cannot value Prestige Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prestige Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Prestige Cash And Equivalents vs. Z Score
Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
Prestige Biologics |
| = | 1.2 |
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Prestige Biologics |
| = | 36.77 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Prestige Cash And Equivalents Comparison
Prestige Biologics is number one stock in cash and equivalents category among its peers.
Prestige Biologics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Prestige Biologics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Prestige Biologics will eventually generate negative long term returns. The profitability progress is the general direction of Prestige Biologics' change in net profit over the period of time. It can combine multiple indicators of Prestige Biologics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. The company was founded in 2015 and is based in Cheongju-si, South Korea. Prestige Biologics is traded on Korean Securities Dealers Automated Quotations in South Korea.
Prestige Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Prestige Biologics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Prestige Biologics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Prestige Biologics' important profitability drivers and their relationship over time.
Use Prestige Biologics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prestige Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prestige Biologics will appreciate offsetting losses from the drop in the long position's value.Prestige Biologics Pair Trading
Prestige Biologics Co Pair Trading Analysis
The ability to find closely correlated positions to Prestige Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prestige Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prestige Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prestige Biologics Co to buy it.
The correlation of Prestige Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prestige Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prestige Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prestige Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Prestige Biologics position
In addition to having Prestige Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Prestige Stock
To fully project Prestige Biologics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Prestige Biologics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Prestige Biologics' income statement, its balance sheet, and the statement of cash flows.